TY - JOUR
T1 - Development of Urinary Diagnostic Biomarker for IgA Nephropathy by Lectin Microarray
AU - Onishi, Yasuhiro
AU - Mise, Koki
AU - Kawakita, Chieko
AU - Uchida, Haruhito A.
AU - Sugiyama, Hitoshi
AU - Sugawara, Ryosuke
AU - Yamaguchi, Satoshi
AU - Yoshida, Michihiro
AU - Mitsuhashi, Toshiharu
AU - Yamada, Masao
AU - Hirabayashi, Jun
AU - Wada, Jun
N1 - Funding Information:
This work was supported by Grant-in-Aid for Scientific Research (C) (21K08230), the Japan Agency for Medical Research and Development (AMED) (19lk1403007h0003 and 21ek0109445h0002), and the Yukiko Ishibashi Foundation (a Grant in 2021).
Funding Information:
Haruhito A. Uchida belongs to the Department of Chronic Kidney Disease and Cardiovascular Disease which is endowed by Chugai Pharmaceutical, MSD, Boehringer Ingelheim, and Kawanishi Holdings. Jun Wada receives speaker honoraria from Astra Zeneca, Daiichi Sankyo, Novartis, Novo Nordisk Pharma, and Tanabe Mitsubishi and receives grant support from Astellas, Baxter, Bayer, Chugai, Dainippon Sumitomo, Kyowa Kirin, Novo Nordisk Pharma, Ono, Otsuka, Tanabe Mitsubishi, and Teijin. Masao Yamada is an employee of Glycotechnica. Any other authors declare no conflicts of interest.
Funding Information:
The authors deeply thank Dr. Motoo Araki for the registration of kidney donors, Ms. Shiina Tokuda and Ms. Saki Yoshida for their supports, and Dr. Yoshia Miyawaki for his gracious suggestion about data analysis. This work was supported by the Okayama University Central Research Laboratory and Center for innovative clinical medicine, Okayama University Hospital.
Publisher Copyright:
© 2021
PY - 2021
Y1 - 2021
N2 - Introduction: The pathogenic roles of aberrantly glycosylated IgA1 have been reported. However, it is unexplored whether the profiling of urinary glycans contributes to the diagnosis of IgAN. Methods: We conducted a retrospective study enrolling 493 patients who underwent renal biopsy at Okayama University Hospital between December 2010 and September 2017. We performed lectin microarray in urine samples and investigated whether c-statistics of the reference standard diagnosis model employing hematuria, proteinuria, and serum IgA were improved by adding the urinary glycan intensity. Results: Among 45 lectins, 3 lectins showed a significant improvement of the models: Amaranthus caudatus lectin (ACA) with the difference of c-statistics 0.038 (95% CI: 0.019-0.058, p < 0.001), Agaricus bisporus lectin (ABA) 0.035 (95% CI: 0.015-0.055, p < 0.001), and Maackia amurensis lectin (MAH) 0.035 (95% CI: 0.015-0.054, p < 0.001). In 3 lectins, each signal plus reference standard showed good reclassification (category-free NRI and relative IDI) and good model fitting associated with the improvement of AIC and BIC. Stratified by eGFR, the discriminatory ability of ACA plus reference standard was maintained, suggesting the robust renal function-independent diagnostic performance of ACA. By decision curve analysis, there was a 3.45% net benefit by adding urinary glycan intensity of ACA to the reference standard at the predefined threshold probability of 40%. Conclusions: The reduction of Gal(β1-3)GalNAc (T-antigen), Sia(α2-3)Gal(β1-3)GalNAc (Sialyl T), and Sia(α2-3)Gal(β1-3)Sia(α2-6)GalNAc (disialyl-T) was suggested by binding specificities of 3 lectins. C1GALT1 and COSMC were responsible for the biosynthesis of these glycans, and they were known to be downregulated in IgAN. The urinary glycan analysis by ACA is a useful and robust noninvasive strategy for the diagnosis of IgAN.
AB - Introduction: The pathogenic roles of aberrantly glycosylated IgA1 have been reported. However, it is unexplored whether the profiling of urinary glycans contributes to the diagnosis of IgAN. Methods: We conducted a retrospective study enrolling 493 patients who underwent renal biopsy at Okayama University Hospital between December 2010 and September 2017. We performed lectin microarray in urine samples and investigated whether c-statistics of the reference standard diagnosis model employing hematuria, proteinuria, and serum IgA were improved by adding the urinary glycan intensity. Results: Among 45 lectins, 3 lectins showed a significant improvement of the models: Amaranthus caudatus lectin (ACA) with the difference of c-statistics 0.038 (95% CI: 0.019-0.058, p < 0.001), Agaricus bisporus lectin (ABA) 0.035 (95% CI: 0.015-0.055, p < 0.001), and Maackia amurensis lectin (MAH) 0.035 (95% CI: 0.015-0.054, p < 0.001). In 3 lectins, each signal plus reference standard showed good reclassification (category-free NRI and relative IDI) and good model fitting associated with the improvement of AIC and BIC. Stratified by eGFR, the discriminatory ability of ACA plus reference standard was maintained, suggesting the robust renal function-independent diagnostic performance of ACA. By decision curve analysis, there was a 3.45% net benefit by adding urinary glycan intensity of ACA to the reference standard at the predefined threshold probability of 40%. Conclusions: The reduction of Gal(β1-3)GalNAc (T-antigen), Sia(α2-3)Gal(β1-3)GalNAc (Sialyl T), and Sia(α2-3)Gal(β1-3)Sia(α2-6)GalNAc (disialyl-T) was suggested by binding specificities of 3 lectins. C1GALT1 and COSMC were responsible for the biosynthesis of these glycans, and they were known to be downregulated in IgAN. The urinary glycan analysis by ACA is a useful and robust noninvasive strategy for the diagnosis of IgAN.
KW - Diagnostic biomarkers
KW - Glomerulonephritis
KW - Glycomics
KW - IgA nephropathy
KW - Lectins
UR - http://www.scopus.com/inward/record.url?scp=85122297024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122297024&partnerID=8YFLogxK
U2 - 10.1159/000520998
DO - 10.1159/000520998
M3 - Article
C2 - 34965524
AN - SCOPUS:85122297024
SN - 0250-8095
JO - American Journal of Nephrology
JF - American Journal of Nephrology
ER -